Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib with or without platinum-pemetrexed chemotherapy as first-line treatment for EGFR-mutated advanced non-small cell lung cancer
jRCT1080224820Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of osimertinib, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080224820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224820.